Insilico and SK Biopharmaceuticals Partner in $2.5B AI Drug Discovery Agreement
Insilico Medicine (ISLMF) has entered a partnership with SK Biopharmaceuticals to develop AI-driven drug candidates for central nervous system neuroimmune disorders, featuring an upfront payment of $18 million and total potential value exceeding $2.5 billion plus royalties.
